Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell...

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Mechanistic target of rapamycin (mTOR) is a critical driver in various cancers, including glioblastoma multiforme (GBM).
• Existing mTOR inhibitors (rapalogs and kinase inhibitors) exhibit limitations in efficacy and tolerability, necessitating the development of more selective agents.
• Glioblastoma multiforme (GBM) remains the most aggressive form of brain cancer with limited treatment options.

Purpose of the Study:

• To identify and develop novel, highly selective mTOR inhibitors specifically targeting glioblastoma multiforme (GBM).
• To explore the N1 position of the pyrazolo[3,4-d]pyrimidine scaffold for improved mTOR inhibition.
• To establish structure-activity relationships (SARs) for potent and selective GBM-targeting compounds.

Main Methods:

• Iterative synthesis and screening of small compound libraries against GBM cell lines.
• Rapid generation of structure-activity relationships (SARs) by prioritizing GBM cell activity.
• Preclinical validation using advanced GBM stem cell models.

Main Results:

• Three rounds of design, synthesis, and screening yielded potent antiproliferative inhibitors.
• The most potent analogs demonstrated superior mTOR activity and selectivity.
• Compound 3n (eALM1137) was identified as a novel, best-in-class mTOR inhibitor with chemical probe characteristics.

Conclusions:

• Novel pyrazolo[3,4-d]pyrimidine derivatives targeting the N1 position show promise as selective mTOR inhibitors.
• Compound 3n (eALM1137) represents a significant advancement in developing targeted therapies for glioblastoma multiforme (GBM).
• The identified compound exhibits characteristics suitable for a chemical probe, facilitating further research into mTOR signaling in cancer.